Related references
Note: Only part of the references are listed.CD47 as a promising therapeutic target in oncology
Hai Zhao et al.
FRONTIERS IN IMMUNOLOGY (2022)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
Hironori Yoshida et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2021)
Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
Anita K. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2021)
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy?
Ni Tong et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
CD47: role in the immune system and application to cancer therapy
Seyed Mohammad Gheibi Hayat et al.
CELLULAR ONCOLOGY (2020)
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Enriqueta Felip et al.
EUROPEAN JOURNAL OF CANCER (2020)
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
Rui Kitadai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer
Oscar Arrieta et al.
CANCER MEDICINE (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy
Rina Fujiwara-Tani et al.
PATHOBIOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
Tomoko Yamamoto Funazo et al.
SCIENTIFIC REPORTS (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Blocking don't eat me signal of CD47-SIRPα in hematological malignancies, an in-depth review
Atlantis Russ et al.
BLOOD REVIEWS (2018)
CD47-signal regulatory protein signaling system and its application to cancer immunotherapy
Yoji Murata et al.
CANCER SCIENCE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Single nucleotide polymorphisms and cancer susceptibility
Na Deng et al.
ONCOTARGET (2017)
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
Takashi Nomizo et al.
SCIENTIFIC REPORTS (2017)
Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer
Xuyao Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The immunophenotype of antigen presenting cells of the mononuclear phagocyte system in normal human liver - A systematic review
Otto Strauss et al.
JOURNAL OF HEPATOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer
Jess Lascorz et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2013)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Role of CD47 as a marker of self on red blood cells
PA Oldenborg et al.
SCIENCE (2000)
Share Paper
